Lab 21, the Cambridge-based laboratory testing company, has expanded into the Chinese market with its syphilis screener.
Speaking of the development, Graham Mullis, Chief Executive of Lab 21 stated, “The Chinese in-vitro diagnostic market has a value in the region of $1.5bn and is the world’s seventh largest, expanding at 15% annually.
“Ours is already the leading syphilis assay in a number of key blood screening markets and we are delighted to make it available in another key region.”
The company have indicated that this is a sign of things to come and they will be registering a number of its diagnostic and blood-banking products over the next 18 months in China.
Looking for a job in science? Click here to search our current science jobs now.
